/EVO
EVO Stock - Evotec SE
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$2.95+0.68%
+$0.02 (+0.68%) • Dec 19
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.7
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.74
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+137.3%upside
Target: $7.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EVO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.92 – $2.98
TARGET (TP)$7.00
STOP LOSS$2.71
RISK/REWARD1:16.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.15
52W High$5.10
52W Low$2.84
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $796.97M | $781.43M | $751.45M | $618.03M | $500.92M |
| Gross Profit | $114.88M | $175.05M | $174.06M | $151.54M | $125.74M |
| Gross Margin | 14.4% | 22.4% | 23.2% | 24.5% | 25.1% |
| Operating Income | $-142,522,000 | $-47,507,000 | $20.85M | $41.00M | $48.56M |
| Net Income | $-196,078,000 | $-83,913,000 | $-175,655,000 | $215.51M | $6.28M |
| Net Margin | -24.6% | -10.7% | -23.4% | 34.9% | 1.3% |
| EPS | $-0.56 | $-0.23 | $-0.49 | $0.65 | $0.02 |
Company Overview
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
33%
Hold / Neutral
7
58%
Sell / Underperform
1
8%
Analyst Consensus🔴 Bearish
4 Bullish8 Neutral/Bearish
Price Targets
$13
Average Target
↑ 323.7% Upside
Now
$6
Low
$13
Average
$16
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 24th 2025 | Deutsche Bank | Upgrade | Hold | - |
| October 7th 2024 | Jefferies | Downgrade | Hold | - |
| August 8th 2024 | Deutsche Bank | Downgrade | Sell | - |
| July 29th 2024 | Morgan Stanley | Downgrade | Equal Weight | $6← $15 |
| July 11th 2024 | Deutsche Bank | Downgrade | Hold | - |
| April 12th 2024 | Deutsche Bank | Upgrade | Buy | - |
| January 18th 2024 | RBC Capital Mkts | Upgrade | Outperform | - |
| June 23rd 2023 | Morgan Stanley | Upgrade | Overweight | $16← $12 |
| June 16th 2023 | BofA Securities | Downgrade | Neutral | $13 |
| June 8th 2023 | Citigroup | Upgrade | Buy | - |
| April 4th 2023 | Morgan Stanley | Upgrade | Equal Weight | $12← $11 |
| December 9th 2022 | H.C. Wainwright | Initiation | Buy | $12 |
| November 16th 2022 | Deutsche Bank | Downgrade | Hold | - |
| August 10th 2022 | Morgan Stanley | Downgrade | Underweight | $16← $23 |
Earnings History & Surprises
EVOBeat Rate
6%
Last 16 quarters
Avg Surprise
-207.0%
EPS vs Estimate
Beats / Misses
1/15
Last 12 quarters
Latest EPS
$-0.14
Q4 2025
EPS Surprise History
Q1 24
-66.7%
$-0.05vs$-0.03
Q2 24
-49.5%
$-0.05vs$-0.03
Q3 24
-222.2%
$-0.29vs$-0.09
Q4 24
-50.0%
$-0.12vs$-0.08
Q2 25
-768.2%
$-0.12vs$0.02
Q2 25
-77.3%
$-0.19vs$-0.11
Q3 25
+19.9%
$-0.14vs$-0.18
Q4 25
-1.4%
$-0.14vs$-0.14
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 5, 2025 | $-0.14 | $-0.14 | -1.4% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.18 | $-0.14 | +19.9% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.11 | $-0.19 | -77.3% | ✗ MISS |
Q2 2025 | Apr 17, 2025 | $0.02 | $-0.12 | -768.2% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.08 | $-0.12 | -50.0% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.09 | $-0.29 | -222.2% | ✗ MISS |
Q2 2024 | May 22, 2024 | $-0.03 | $-0.05 | -49.5% | ✗ MISS |
Q1 2024 | Feb 26, 2024 | $-0.03 | $-0.05 | -66.7% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.05 | $-0.12 | -140.0% | ✗ MISS |
Q3 2023 | Aug 29, 2023 | $-0.04 | $-0.04 | -10.9% | ✗ MISS |
Q2 2023 | May 12, 2023 | $0.10 | $-0.08 | -180.0% | ✗ MISS |
Q1 2023 | Mar 29, 2023 | $0.10 | $-0.13 | -230.0% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $0.08 | $-0.26 | -419.5% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.02 | $-0.08 | -375.1% | ✗ MISS |
Q2 2022 | May 11, 2022 | $0.06 | $-0.23 | -483.3% | ✗ MISS |
Q2 2022 | Apr 12, 2022 | $0.07 | $-0.11 | -257.1% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | — | $0.95 | — | — |
Q3 2021 | Aug 11, 2021 | — | $0.43 | — | — |
Q2 2021 | May 11, 2021 | — | $0.38 | — | — |
Q1 2021 | Mar 25, 2021 | — | $0.00 | — | — |
Latest News
Evotec Closed Its Previously Reported Sale Of The Just-evotec Biologics Toulouse Site Plus An Indefinite Technology License To Its Continuous Manufacturing Platform Technology To Sandoz, Potential Payments Of Over $650M Plus Royalties Of Up To 10 Biosimilar Molecules
📈 PositiveBenzinga•Dec 8, 2025, 10:51 AM•Also:
Evotec And Bayer Kidney Disease Collaboration Advances SEMA3A Monoclonal Antibody Program Into Phase 2 Clinical Development
📈 PositiveBenzinga•Dec 4, 2025, 08:49 AM•Also:
Evotec Receives $5M Milestone Payment From Bristol Myers Squibb Following FDA IND Acceptance Under Strategic Protein Degradation Partnership
📈 PositiveBenzinga•Nov 12, 2025, 07:23 AM•Also:
Evotec SE Launches Share Repurchase Program To Acquire Up To 290K Shares At A Total Purchase Price Of Up To €3 Million
📈 PositiveBenzinga•Nov 6, 2025, 02:43 PM
Evotec shares are trading lower after the company reported worse-than-expected Q3 sales results.
📉 NegativeBenzinga•Nov 5, 2025, 02:20 PM
Evotec Affirms FY2025 Sales Guidance of $861.690M-$907.042M
📈 PositiveBenzinga•Nov 5, 2025, 08:28 AM
Evotec Q3 EPS $(0.14), Inline, Sales $191.620M Miss $237.320M Estimate
📉 NegativeBenzinga•Nov 5, 2025, 07:13 AM
Evotec To Sell Evotec Biologics Toulouse Facility To Sandoz AG For ~$350M In Cash
📈 PositiveBenzinga•Nov 4, 2025, 09:35 PM•Also:
Evotec Reports $25M Payment From Bristol Myers Squibb For Achievements In Strategic Neuroscience Partnership Focused On Disease-Modifying Therapies
📈 PositiveBenzinga•Oct 27, 2025, 07:06 AM•Also:
Frequently Asked Questions about EVO
What is EVO's current stock price?
Evotec SE (EVO) is currently trading at $2.95 per share. The stock has moved +0.68% today.
What is the analyst price target for EVO?
The average analyst price target for EVO is $7.00, based on 1 analyst.
What sector is Evotec SE in?
Evotec SE operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is EVO's market cap?
Evotec SE has a market capitalization of $1.05 billion, making it a small-cap company.
Does EVO pay dividends?
No, Evotec SE does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALVO
Alvotech
$4.90
Mkt Cap: $1.5B
AZTA
Azenta, Inc.
$34.43
Mkt Cap: $1.6B
HROW
Harrow Health, Inc.
$46.40
Mkt Cap: $1.7B
NVCR
NovoCure Limited
$12.84
Mkt Cap: $1.4B
PCRX
Pacira BioSciences, Inc.
$26.35
Mkt Cap: $1.2B
PHVS
Pharvaris N.V.
$25.59
Mkt Cap: $1.7B
SDGR
Schrödinger, Inc.
$17.66
Mkt Cap: $1.3B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
TDOC
Teladoc Health, Inc.
$7.23
Mkt Cap: $1.3B
TLRY
Tilray Brands, Inc.
$11.16
Mkt Cap: $1.2B
Explore stocks similar to EVO for comparison